Shilpa Medicare Ltd
NSE:SHILPAMED

Watchlist Manager
Shilpa Medicare Ltd Logo
Shilpa Medicare Ltd
NSE:SHILPAMED
Watchlist
Price: 650.75 INR 1.85% Market Closed
Market Cap: 63.6B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one SHILPAMED stock under the Base Case scenario is 1 181.47 INR. Compared to the current market price of 650.75 INR, Shilpa Medicare Ltd is Undervalued by 45%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SHILPAMED Relative Value
Base Case
1 181.47 INR
Undervaluation 45%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.1
P/S
P/S
Price to Sales
5.1
vs History
14
vs Industry
24
Median 3Y
3.1
Median 5Y
3.7
Industry
2.4
Forward
4.5
More Details
72.1
P/E
P/E
Price to Earnings
72.1
vs History
44
vs Industry
5
Median 3Y
70.4
Median 5Y
62.2
Industry
20.5
Forward
50.1
More Details
42.4
P/OCF
P/OCF
Price to OCF
42.4
vs History
41
vs Industry
10
Median 3Y
31.6
Median 5Y
36.1
Industry
15.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
3
Median 3Y
-8.2
Median 5Y
9.5
Industry
23.1
More Details
2.7
P/B
P/B
Price to Book Value
2.7
vs History
36
vs Industry
27
Median 3Y
2
Median 5Y
2.4
Industry
2
More Details
5.3
EV/S
EV/S
Enterprise Value to Sales
5.3
vs History
17
vs Industry
23
Median 3Y
3.4
Median 5Y
4.2
Industry
2.5
Forward
4.7
More Details
7.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
7.8
vs History
15
vs Industry
26
Median 3Y
5.4
Median 5Y
6.2
Industry
4.9
More Details
21
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
21
vs History
42
vs Industry
17
Median 3Y
20.6
Median 5Y
20.5
Industry
12.3
Forward
17.3
More Details
32
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
32
vs History
65
vs Industry
13
Median 3Y
39.5
Median 5Y
36.7
Industry
15.5
Forward
24.7
More Details
44
EV/OCF
EV/OCF
Enterprise Value to OCF
44
vs History
38
vs Industry
9
Median 3Y
35.1
Median 5Y
39.3
Industry
14.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-98
Median 5Y
-48.5
Industry
17.5
More Details
2.2
EV/IC
EV/IC
Enterprise Value to IC
2.2
vs History
17
vs Industry
32
Median 3Y
1.5
Median 5Y
1.8
Industry
1.8
More Details

Multiples Across Competitors

SHILPAMED Competitors Multiples
Shilpa Medicare Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Shilpa Medicare Ltd
NSE:SHILPAMED
63.6B INR 5.1 72.1 21 32
US
Eli Lilly and Co
NYSE:LLY
720.3B USD 14.7 64.6 34.9 38.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.1B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.4 12.8 14.6
CH
Roche Holding AG
SIX:ROG
207.9B CHF 3.4 25.1 9.4 11
CH
Novartis AG
SIX:NOVN
179.6B CHF 4 16.8 9.9 13.3
UK
AstraZeneca PLC
LSE:AZN
159.3B GBP 3.9 27.2 130.4 196.6
US
Merck & Co Inc
NYSE:MRK
203.1B USD 3.2 11.7 8.7 10.5
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
131B USD 2.1 16.6 7.2 10.2
P/E Multiple
Earnings Growth PEG
IN
Shilpa Medicare Ltd
NSE:SHILPAMED
Average P/E: 30.1
72.1
147%
0.5
US
Eli Lilly and Co
NYSE:LLY
64.6
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.4
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.1
32%
0.8
CH
Novartis AG
SIX:NOVN
16.8
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.2
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.7
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.6
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Shilpa Medicare Ltd
NSE:SHILPAMED
Average EV/EBITDA: 395.9
21
52%
0.4
US
Eli Lilly and Co
NYSE:LLY
34.9
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.4
6%
1.6
CH
Novartis AG
SIX:NOVN
9.9
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.4
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.7
9%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.2
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Shilpa Medicare Ltd
NSE:SHILPAMED
Average EV/EBIT: 1 700
32
74%
0.4
US
Eli Lilly and Co
NYSE:LLY
38.1
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.6
14%
1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
13.3
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
196.6
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10.5
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
10%
1

See Also

Summary
SHILPAMED intrinsic value, competitors valuation, and company profile.
DCF Valuation
SHILPAMED stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SHILPAMED stock valuation using valuation multiples.
Wall Street Estimates
SHILPAMED price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SHILPAMED stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 254,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.